Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics-Reference-Cited by-同舟云学术

Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics

Published:2016-08 Issue: Volume:236 Page:100-116
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Thompson Pamela,Fleming Ryan,Bezabeh Binyam,Huang Fengying,Mao Shenlan,Chen Cui,Harper Jay,Zhong Haihong,Gao Xizhe,Yu Xiang-Qing,Hinrichs Mary Jane,Reed Molly,Kamal Adeela,Strout Patrick,Cho Song,Woods Rob,Hollingsworth Robert E.,Dixit Rakesh,Wu Herren,Gao Changshou,Dimasi Nazzareno

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference38 articles.

1. Comparing antibody and small-molecule therapies for cancer;Imai;Nat. Rev. Cancer,2006

2. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1;Giaccone;J. Clin. Oncol.,2004

3. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2;Herbst;J. Clin. Oncol.,2004

4. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC);Rosell;J. Clin. Oncol.,2004

5. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer;Thienelt;J. Clin. Oncol.,2005

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability;Cell Reports;2023-12

2. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer;Molecular Cancer Therapeutics;2023-06-09

3. Plant polysaccharide-based conjugates for anticancer drug delivery;Plant Polysaccharides as Pharmaceutical Excipients;2023

4. Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody–Drug Conjugate Efficacy and Toxicity;Molecular Cancer Therapeutics;2022-12-02

5. Interconversion of Unexpected Thiol States Affects the Stability, Structure, and Dynamics of Antibody Engineered for Site-Specific Conjugation;Bioconjugate Chemistry;2021-08-09